TY  - JOUR
T1  - CLINICAL OUTCOMES OF COMBINED GLYCOPROTEIN IIB/IIIA INHIBITORS AND P2Y12 RECEPTOR ANTAGONIST IN ELECTIVE PCI FOR PATIENTS OVER 65
TT  - YAŞ ÜSTÜ HASTALARDA ELEKTİF PKG’DE GLİKOPROTEİN IIB/IIIA İNHİBİTÖRLERİ İLE P2Y12 RESEPTÖR ANTAGONİSTİ KOMBİNASYONUNUN KLİNİK SONUÇLARI
AU  - Akgün, Arzu Neslihan
AU  - Has Hasırcı, Senem
AU  - Karaçağlar, Emir
PY  - 2025
DA  - November
Y2  - 2025
JF  - Eskisehir Medical Journal
JO  - Eskisehir Med J
PB  - Eskişehir Şehir Hastanesi
WT  - DergiPark
SN  - 2718-0948
SP  - 289
EP  - 292
VL  - 6
IS  - 3
LA  - en
AB  - Introduction: Glycoprotein IIb/IIIa inhibitors (GPIs) are potent antiplatelet agents used during percutaneous coronary intervention (PCI) to reduce thrombotic complications. While their efficacy in acute coronary syndromes is established, their role in elective PCI, particularly among elderly patients, remains uncertain.Methods: This retrospective, single-center study included 85 patients aged ≥65 years who underwent elective PCI between 2021–2023 and received GPIs due to high thrombus burden or no-reflow. All patients received aspirin and a P2Y12 inhibitor (clopidogrel , prasugrel, or ticagrelor); abciximab or tirofiban was used as the GPI. Clinical, laboratory, and procedural data were analyzed, focusing on major bleeding, haemoglobin drop, transfusion requirement, and hospital stay.Results: The mean age was 70 years and 83% were male. Tirofiban was administered in 83% and abciximab in 17% of cases. Major bleeding occurred in 26%, most frequently in the abciximab plus potent P2Y12 group, though differences were not statistically significant. Hospital stay was longer in patients receiving abciximab. Haemoglobin drop was significantly greater across groups, but no difference was observed in haemoglobin levels at one-month and one-year follow-up. Creatinine values were comparable. No stent thrombosis or mortality was reported.Conclusions: In elderly patients undergoing elective PCI, GPIs appear to be the main determinant of bleeding risk, with no additional impact from the choice of P2Y12 inhibitor. These findings emphasize the need for a selective approach to GPI use in this setting
KW  - Glycoprotein IIb/IIIa inhibitors; P2Y12 inhibitors; elective PCI; bleeding; elderly patients
KW  - Glycoprotein IIb/IIIa inhibitors
KW  - P2Y12 inhibitors
KW  - elective PCI
KW  - bleeding
N2  - Giriş: Glikoprotein IIb/IIIa inhibitörleri (GPI’ler), perkütan koroner girişim (PKG) sırasında trombotik komplikasyonları azaltmak için kullanılan güçlü antiplatelet ajanlardır. Akut koroner sendromlarda etkinlikleri gösterilmiş olsa da, elektif PKG’de özellikle yaşlı hastalarda klinik yararları ve güvenlik profilleri tartışmalıdır.Yöntemler: Bu retrospektif, tek merkezli çalışmaya, 2021–2023 yılları arasında elektif PKG sırasında yüksek trombüs yükü veya no-reflow nedeniyle GPI tedavisi verilen, 65 yaş ve üzeri toplam 85 hasta dahil edildi. Tüm hastalara asetilsalisilik asit ve bir P2Y12 inhibitörü (klopidogrel, prasugrel veya tikagrelor) uygulandı; GPI olarak abciximab veya tirofiban kullanıldı. Klinik, laboratuvar ve işlem verileri incelendi; majör kanama, hemoglobin düşüşü, transfüzyon ihtiyacı ve hastanede kalış süresi değerlendirildi.Bulgular: Hastaların ortalama yaşı 70 yıl olup %83’ü erkekti. Tirofiban %83, abciximab %17 oranında kullanıldı. Majör kanama oranı %26 idi ve en yüksek oran abciximab + potent P2Y12 grubunda gözlendi. Ancak gruplar arasında istatistiksel fark yoktu. Hastanede kalış süresi abciximab alanlarda daha uzundu. Hemoglobin düşüşü gruplar arasında anlamlı farklılık gösterirken, 1. ay ve 1. yılda Hb değerleri benzerdi. Kreatinin düzeyleri arasında fark yoktu, mortalite veya stent trombozu görülmedi.Sonuç: Yaşlı elektif PKG hastalarında GPI tedavisi kanama riskini artıran temel faktördür. P2Y12 inhibitörünün klopidogrel veya potent ajan olmasının kanama üzerine ek etkisi görülmemiştir. Bulgular, GPI kullanımında seçici yaklaşımın önemini vurgulamaktadır
CR  - De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705–13.
CR  - Blanchart K, Heudel T, Ardouin P, et al. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pretreated with newer P2Y12 inhibitors. Clin Cardiol. 2021;44(8):1080–8.
CR  - Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903.
CR  - French DL, Seligsohn U. Platelet glycoprotein IIb/IIIa receptors and Glanzmann’s thrombasthenia. Arterioscler Thromb Vasc Biol. 2000;20(3):607–10.
CR  - Tigen MK, Özdil MH, Çinçin A, et al. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: real-life data. Anatol J Cardiol. 2021;25(10):699.
CR  - Collet J-P, Thiele H, Barbato E, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.
CR  - Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.
CR  - O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 analysis. J Am Coll Cardiol. 2009;54:678–85.
CR  - Shimada YJ, Bansilal S, Wiviott SD, et al.; PLATO Investigators. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the PLATO trial. Am Heart J. 2016;177:1–8.
CR  - Roule V, Agueznai M, Sabatier R, et al. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: a meta-analysis of pivotal trials. Platelets. 2017;28:174–81.
CR  - Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala U. The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials. Vasc Pharmacol. 2025;159:107500.
UR  - https://dergipark.org.tr/tr/pub/eskisehirmedj/issue//1776009
L1  - https://dergipark.org.tr/tr/download/article-file/5204000
ER  -